STTR Phase II: An On-Demand, Computational and Microfluidic-Driven Cell-Free Protein Engineering Platform

STTR II 期：按需、计算和微流体驱动的无细胞蛋白质工程平台

• 批准号: 1758591
• 负责人: Zachary Sun
• 金额: $ 75万
• 依托单位: SYNVITROBIO INC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-03-01 至 2023-08-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1758591&HistoricalAwards=false
• 关键词: STTR; Phase; II; Demand; Computational

The broader impact/commercial potential of this Small Business Technology Transfer (STTR) will be to develop a platform to accelerate the engineering of biological products, including enzymes and pathways, for production of chemicals, additives, and therapeutics. Enzymes are used in household materials (detergents and cleaners) and in chemical processes (cheese production, and bioremediation of waste). Pathways can produce bioplastics from sugar by engineered gut bacteria, or artemisinin (an antimalarial) from sugar by yeast. These biological products are engineered in cells. Cellular engineering, however, requires extensive scientific expertise, financial and material resources, and time. This project will design an engineering platform that eliminates production in cells. The goal is to simplify engineering and decrease costs 20-100 fold, and decrease time 2-5 fold. This results in a faster time-to-market for novel biological products and additional information to inform the engineering process. This STTR Phase II project proposes to utilize cell-free systems to speed up enzyme and pathway (metabolic) engineering. Cell-free systems can catalyze reactions without cellular complexity and without the need to maintain cellular growth. The goal of the project is to continue to develop a platform that can take as input user enzyme and pathway engineering questions and produce as output assay data. The primary focus is on developing computational methods for identification and optimization of enzymes and pathways for testing, molecular biological methods for assembling DNA, microfluidic methods for ultra-high-throughput analysis of cell-free expressions (10e7 samples), and analytical methods for detection. A secondary focus is the demonstration of this platform through cytochrome P450 engineering. Success with the primary focus demonstrates feasibility of replacing cellular engineering with faster and higher-throughput cell-free engineering processes. Success with the secondary focus produces directly-relevant enzymes for metabolic engineering pathways utilizing cytochrome P450s (e.g., natural products, bio-catalysis).This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这种小型企业技术转移（STTR）的更广泛的影响/商业潜力将是开发一个平台，以加速包括酶和途径在内的生物产品的工程，用于生产化学，添加剂和治疗剂。酶用于家用材料（洗涤剂和清洁剂）和化学过程（奶酪生产和废物生物修复）中。途径可以通过工程肠道细菌从糖中产生生物塑料，或者通过酵母从糖中产生青蒿素（一种抗菌素）。这些生物产品是在细胞中设计的。但是，蜂窝工程需要广泛的科学专业知识，财务和物质资源以及时间。该项目将设计一个消除细胞生产的工程平台。目标是简化工程并降低成本20-100倍，并减少时间2-5倍。这导致了新型生物产品和其他信息的更快上市时间，以告知工程过程。该STTR II期项目提议利用无细胞的系统来加快酶和途径（代谢）工程。无细胞系统可以催化反应而无需细胞复杂性，而无需维持细胞生长。该项目的目的是继续开发一个平台，该平台可以作为输入用户酶和途径工程问题并产生作为输出测定数据。主要的重点是开发用于鉴定和优化酶和测试途径的计算方法，用于组装DNA的分子生物学方法，用于无细胞表达（10E7样品）超高通量分析的微流体方法以及用于检测的分析方法。次要的重点是通过细胞色素P450工程进行该平台的演示。主要重点的成功表明，用更快，更高的无细胞工程过程替换细胞工程的可行性。次要焦点的成功生产了使用细胞色素P450S的代谢工程途径的直接相关的酶（例如，天然产品，生物催化）。这项奖项反映了NSF的法定任务，并被认为是通过基金会的知识分子功能和广泛影响的评估来评估Criteria的智力优点和广泛影响。